Why the study?
Does AAV-mediated knockdown of phospholamban improve contractility and calcium handling in cardiomyocytes?
Population
Cultured cardiomyocytes and mice
Design
Preclinical
Key result
AAV-delivered shRNAs targeting phospholamban significantly reduced PLN levels and improved contractility and calcium handling in cultured cardiomyocytes and mouse hearts.
Authors
Loading...
May support AAV-shRNA development for heart failure; leaves open translation from mouse models to clinical use.
Does AAV-mediated knockdown of phospholamban improve contractility and calcium handling in cardiomyocytes?
AAV-mediated knockdown of phospholamban improves contractility and calcium handling in cardiomyocytes, offering a potential therapeutic strategy for chronic heart failure.
Andino et al. (2007) studied chronic heart failure. AAV-delivered small hairpin RNAs (shRNAs) targeting phospholamban was evaluated on PLN RNA and protein levels, cell shortening, relaxation, and calcium decay. AAV-delivered shRNAs targeting phospholamban significantly reduced PLN levels and improved contractility and calcium handling in cultured cardiomyocytes and mouse hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: